FIELD: medicine.
SUBSTANCE: invention refers to medicine and can be used for prediction of developing cardiotoxicity in HER2 patients with positive breast cancer of initially low / moderate cardiovascular risk receiving a targeted therapy with trastuzumab after anthracycline-containing chemotherapy. That is ensured by echocardiography with determination of total longitudinal LV deformation (GLS). Decrease in the given ≥10 % value after the termination of anthracycline-containing chemotherapy compared to the initial value indicates a high risk of developing cardiotoxicity in the therapy with trastuzumab.
EFFECT: invention enables assessing the risk of developing cardiotoxicity during therapy with trastuzumab in the above category of patients.
1 cl, 1 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR ASSESSING SUBCLINICAL CARDIOTOXICITY OF CHEMO- AND TARGETED THERAPY USING ECHOCARDIOGRAPHIC DIAGNOSTICS | 2022 |
|
RU2815813C1 |
| METHOD FOR PREDICTION OF SUBACUTE ANTHRACYCLINE-MEDIATED CARDIOTOXICITY DEVELOPMENT IN ONCOLOGICAL PATIENTS | 2020 |
|
RU2744682C1 |
| METHOD FOR PREDICTION OF ANTHRACYCLINE-INDUCED CARDIOTOXICITY IN WOMEN WITH BREAST CANCER | 2019 |
|
RU2714683C1 |
| METHOD FOR PREVENTING ANTHRACYCLINE CARDIOTOXICITY IN PATIENTS WITH BREAST CANCER | 2014 |
|
RU2546399C1 |
| METHOD OF MANAGING PATIENTS WITH CHRONIC LYMPHATIC LEUKEMIA IN A POLYCHEMOTHERAPY ACCORDING TO A FCR SCHEME AIMED AT PREVENTING CARDIOTOXICITY | 2019 |
|
RU2722111C1 |
| METHOD FOR PREDICTING DEVELOPMENT OF CARDIOTOXICITY IN PATIENTS WITH BREAST CANCER WITHIN 12 MONTHS AFTER CHEMOTHERAPY WITH ANTRACYCLIC DRUGS | 2018 |
|
RU2680139C1 |
| METHOD FOR PREDICTING PROGRESSION OF ANTHRACYCLINE-INDUCED CHRONIC HEART FAILURE IN PATIENTS WITH BREAST CANCER WITHIN 24 MONTHS | 2022 |
|
RU2793672C1 |
| METHOD FOR PRODUCING ULTRASONIC ANTRACYCLINE- INDUCED CARDIOTOXICITY EVALUATION IN ONCOLOGICAL PATIENTS | 2002 |
|
RU2225166C2 |
| METHOD FOR PREDICTING THE PROGRESSION OF CHRONIC HEART FAILURE IN PATIENTS WITH BREAST CANCER AFTER ANTHRACYCLINE CHEMOTHERAPY | 2022 |
|
RU2790788C1 |
| METHOD FOR PREDICTING THE RISK OF DEVELOPING SUBCLINICAL LEFT VENTRICULAR SYSTOLIC DYSFUNCTION IN THE PATIENTS WITH CHRONIC LYMPHATIC LEUKEMIA IN THE CHEMOTHERAPY IN THE FCR MODE | 2019 |
|
RU2727003C1 |
